StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Gyre Therapeutics's total assets was $201.25M at Sep 30, 2026. For fiscal 2025 it was $219.76M, up 75.2% from the year before. Over ten years it grew 12.2% a year on average. The highest annual figure on record is $262.79M in fiscal 2010.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$219.76M+75.2%
FY2024Dec 31, 2024$125.41M+7.6%
FY2023Dec 31, 2023$116.54M+37.5%
FY2022Dec 31, 2022$84.75M+52.3%
FY2021Dec 31, 2021$55.66M-41.3%
FY2020Dec 31, 2020$94.85M-3.8%
FY2019Dec 31, 2019$98.55M-21.1%
FY2018Dec 31, 2018$124.92M+216.1%
FY2017Dec 31, 2017$39.51M+3.7%
FY2016Dec 31, 2016$38.09M-45.2%
FY2015Dec 31, 2015$69.52M+2232.1%
FY2014Dec 31, 2014$2.98M-98.0%
FY2013Dec 31, 2013$145.87M-23.1%
FY2012Dec 31, 2012$189.58M-26.6%
FY2011Dec 31, 2011$258.13M-1.8%
FY2010Dec 31, 2010$262.79M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$201.25M+26.3%
Q2 FY2026Jun 30, 2026$199.26M+30.5%
Q1 FY2026Mar 31, 2026$162.02M+24.8%
Q4 FY2025Dec 31, 2025$219.76M+75.2%
Q3 FY2025Sep 30, 2025$159.38M+27.3%
Q2 FY2025Jun 30, 2025$152.65M+26.2%
Q1 FY2025Mar 31, 2025$129.79M+6.4%
Q4 FY2024Dec 31, 2024$125.41M+7.6%
Q3 FY2024Sep 30, 2024$125.24M+1156.9%
Q2 FY2024Jun 30, 2024$120.93M+875.7%
Q1 FY2024Mar 31, 2024$122.01M+550.7%
Q4 FY2023Dec 31, 2023$116.54M+37.5%
Q3 FY2023Sep 30, 2023$9.96M-67.9%
Q2 FY2023Jun 30, 2023$12.39M-85.1%
Q1 FY2023Mar 31, 2023$18.75M-53.4%
Q4 FY2022Dec 31, 2022$84.75M+52.3%
Q3 FY2022Sep 30, 2022$31.02M-60.5%
Q2 FY2022Jun 30, 2022$83.37M-18.1%
Q1 FY2022Mar 31, 2022$40.27M-66.2%
Q4 FY2021Dec 31, 2021$55.66M-41.3%
Q3 FY2021Sep 30, 2021$78.54M-29.8%
Q2 FY2021Jun 30, 2021$101.79M-17.7%
Q1 FY2021Mar 31, 2021$119.08M+7.7%
Q4 FY2020Dec 31, 2020$94.85M-3.8%
Q3 FY2020Sep 30, 2020$111.80M+21.8%
Q2 FY2020Jun 30, 2020$123.68M+22.6%
Q1 FY2020Mar 31, 2020$110.56M-1.2%
Q4 FY2019Dec 31, 2019$98.55M-21.1%
Q3 FY2019Sep 30, 2019$91.79M-31.2%
Q2 FY2019Jun 30, 2019$100.87M-27.7%
Q1 FY2019Mar 31, 2019$111.87M-23.3%
Q4 FY2018Dec 31, 2018$124.92M+216.1%
Q3 FY2018Sep 30, 2018$133.42M+287.9%
Q2 FY2018Jun 30, 2018$139.54M+252.1%
Q1 FY2018Mar 31, 2018$145.89M+402.0%
Q4 FY2017Dec 31, 2017$39.51M+3.7%
Q3 FY2017Sep 30, 2017$34.39M–
Q2 FY2017Jun 30, 2017$39.63M–
Q1 FY2017Mar 31, 2017$29.06M–
Q4 FY2016Dec 31, 2016$38.09M–

More Gyre Therapeutics figures

See a number that looks wrong?